Alere to Develop Simple, Affordable Point-of-Care Nucleic Acid Test for Tuberculosis & Expand Manufacturing for POC HIV Viral Load Platform WALTHAM, Mass., March 1, 2013 /PRNewswire/ -- Alere Inc.
The $21.6 million grant will fund the development of a tuberculosis assay, which will be designed for use in both resource-constrained and well-resourced settings. It will also support the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results